Controlled clinical study of a long-term treatment of chronic obstructive lung disease using a combination of fenoterol and ipratropium bromide in aerosol form.
A group of patients suffering from chronic obstructive lung disease, selected according to clinical criteria and respiratory function, were treated daily for at least 84 days using a metered aerosol containing a combination of a beta 2-agonist (fenoterol) and an atropine-like drug (ipratropium bromide). Every 14 days, respiratory and cardiovascular function was measured and analysed statistically. Information was compiled daily by the patients themselves on dyspnoea, cough, peak flow, any increase in dosage over the recommended dose and any side-effects that might have developed. The results obtained demonstrated that the combination of fenoterol and ipratropium bromide produced clear improvements in respiratory function and symptomatology throughout the observation period. The drug was well tolerated by the majority of patients.
D000336:Aerosols; D001286:Atropine Derivatives / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003371:Cough / Q000150:complications / Q000503:physiopathology; D004417:Dyspnea / Q000150:complications / Q000503:physiopathology; D005280:Fenoterol / Q000009:adverse effects / Q000627:therapeutic use*; D005541:Forced Expiratory Volume; D006801:Humans; D009241:Ipratropium / Q000009:adverse effects / Q000627:therapeutic use*; D008173:Lung Diseases, Obstructive / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012115:Residual Volume; D013997:Time Factors
D000336:Aerosols; D001286:Atropine Derivatives; D005280:Fenoterol; D009241:Ipratropium